{"filings":[{"id":94133,"accession_number":"0001193125-26-211867","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeonaBio Q1 2026 net loss $32.9M ($1.73/share); cash burn $20.9M; ELAINE-3 enrollment target Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.9M ($1.73 per share) vs $9.1M ($2.34) in Q1 2025, driven by higher R&D spend.","Cash, equivalents and investments $67.7M at March 31, 2026, down from $88.3M at Dec 31, 2025.","R&D expenses $10.3M (up 139% YoY) due to Phase 3 ELAINE-3 lasofoxifene trial costs.","Expects to complete enrollment of Phase 3 ELAINE-3 in Q4 2026; topline data 2H 2027.","Appointed Fred Callori, Natalie Holles, Peter Silverman to Board; John Fluke Jr. retired."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106280,"accession_number":"0001193125-26-134097","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K/A","filed_at":"2026-03-31T23:59:59+00:00","items":["9.01","2.01","1.01"],"status":"ready","headline":"LeonaBio files amended 8-K on Sermonix license, provides ELAINE-3 cost and timeline update","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["SEC granted waiver from providing Sermonix financial statements; license deal treated as business acquisition under Regulation S-X.","Sermonix reported ELAINE-3 cash expenditures of $14M (2023), $12M (2024), $5M (2025 through Dec 18).","LeonaBio expects $45M (2026) and $30M (2027) in ELAINE-3 cash spend; made ~$11M from Dec 18–31, 2025.","ELAINE-3 protocol amended to increase sample size from 500 to up to 600; enrollment completion targeted Q4 2026, topline data H2 2027.","License agreement grants LeonaBio exclusive rights to lasofoxifene for oncology outside Retained Territory."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106283,"accession_number":"0001193125-26-126579","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LeonaBio reports FY2025 net loss $105.6M; acquires Phase 3 lasofoxifene, raises $90M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $105.6M ($24.70 per share) for FY2025 vs $96.9M loss in FY2024; R&D expenses rose to $85.6M on lasofoxifene license costs.","Cash and investments $88.3M at Dec 31, 2025, up from $51.3M year-end 2024; $90M private placement closed with potential $146M from warrant exercises.","Exclusive global license acquired for Phase 3 lasofoxifene (SERM) for ESR1-mutated metastatic breast cancer; ELAINE-3 enrollment completion expected 4Q2026, topline data 2H2027.","ATH-1105 Phase 2 proof-of-concept trial in ALS patients on track to initiate in 2H2026; Phase 1 data showed favorable safety and CNS penetration.","G&A expenses decreased to $16.7M from $26.1M, reflecting cost efficiencies; company renamed from Athira to LeonaBio in Jan 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106282,"accession_number":"0001193125-26-116123","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"LeonaBio shareholders approve 2026 equity plan, 4x authorized share increase, and Sermonix warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 90M to 400M; total capital stock from 190M to 500M.","2026 Equity Incentive Plan approved: up to 5.7M shares initially, plus potential additions from lapsed 2020 Plan awards.","Stockholders approved issuance of 5,502,402 shares upon exercise of Sermonix pre-funded warrant.","Issuance to Sermonix and Perceptive Advisors exceeding 19.99% beneficial ownership also approved.","2026 Plan includes annual evergreen increase equal to the lesser of 5% of outstanding shares or Board-determined amount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106281,"accession_number":"0001193125-26-008904","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["5.03","7.01","8.01","5.02","9.01"],"status":"ready","headline":"Athira Pharma renames to LeonaBio (LONA); lasofoxifene Phase 3 >50% enrolled; CFO gets new severance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change to LeonaBio effective Jan 9, 2026; ticker to LONA on Nasdaq starting Jan 12.","Phase 3 ELAINE-3 trial of lasofoxifene >50% enrolled; topline data expected mid-2027.","CFO Robert Renninger entered amended change in control severance agreement; base salary increased to $460,000.","Name change reflects Dec 2025 acquisition of lasofoxifene rights, with $90M upfront financing and potential additional $146M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122594,"accession_number":"0001193125-25-323692","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Athira Pharma raises ~$90M via PIPE and licenses lasofoxifene from Sermonix","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["PIPE gross proceeds ~$90M; investors include Commodore, TCGX, Perceptive; priced at $6.35/share with warrants.","Sermonix license grants exclusive rights to oral lasofoxifene outside Asia; $34.9M equity issued to Sermonix.","Milestone payments to Sermonix up to $100M; royalties from sub-single to low-single digit percentages.","Ligand agreement imposes separate milestones up to $21M and mid-single to low-double digit royalties.","Commodore and TCGX each get board designee if holding ≥5%; Company to seek resignation of two current directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122591,"accession_number":"0001193125-25-323786","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K/A","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Athira Pharma licenses lasofoxifene rights, raises $90M in PIPE financing","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Licensed exclusive rights to oral lasofoxifene from Sermonix and Ligand for $34.9M in equity, plus monthly payments and up to $100M milestones.","PIPE raises ~$90M gross from Commodore, TCGX, Perceptive and others at $6.35/share with warrants exercisable after ELAINE-3 milestones.","Both PIPE and Sermonix closings expected December 23, 2025; proceeds for working capital, excluding debt repayment or stock redemption.","Commodore and TCGX each get board designation rights if holding 5%+; company to seek resignation of two current directors within 6 months.","Joseph Edelman (Perceptive) is a board member; Perceptive affiliates hold ~29% of Sermonix capital stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122593,"accession_number":"0001193125-25-269506","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma reports Q3 2025 net loss of $6.6M, cash at $25.2M; exploring strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.6M ($1.68 per share) vs $28.7M ($7.46 split-adjusted) in Q3 2024.","Cash and investments $25.2M as of Sept 30, 2025, down from $51.3M at Dec 31, 2024.","R&D expenses fell to $2.8M from $17.9M; G&A expenses $4.1M vs $7.6M year-over-year.","Company continues to explore strategic alternatives to maximize stockholder value; engaged Cantor Fitzgerald.","Phase 1 data for ALS candidate ATH-1105 showed favorable safety, dose-proportional PK, and CNS penetration."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122592,"accession_number":"0001193125-25-229293","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":[],"status":"ready","headline":"Athira Pharma regains Nasdaq minimum bid price compliance; delisting risk removed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Oct 2, 2025 that closing bid price was $1.00+ for ten consecutive days.","Compliance with Nasdaq minimum bid requirement is regained and the matter is closed.","Previously notified of deficiency on Oct 16, 2024 when stock fell below $1.00 for 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139283,"accession_number":"0000950170-25-114093","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Athira Pharma to effect 10-for-1 reverse stock split on Sep 17 to meet Nasdaq minimum bid price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Sept 17 at 5pm ET; shares start trading split-adjusted on Sep 18 under ticker ATHA.","Every 10 pre-split shares convert to 1; authorized common shares reduced from 900M to 90M.","Purpose: increase share price to comply with Nasdaq's $1.00 minimum bid requirement.","Fractional shares paid in cash; CUSIP changes to 04746L203.","No action needed by book-entry or street-name holders; Computershare is exchange agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139282,"accession_number":"0000950170-25-105029","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q2 net loss narrows to $7.0M; cash burn slows; ATH-1105 Phase 1 data support ALS development","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.0M ($0.18/sh) vs $26.9M ($0.70) in Q2 2024, driven by lower R&D and G&A spend.","Cash, equivalents and investments $29.8M as of June 30, 2025, down from $51.3M at Dec 31, 2024.","R&D expenses fell to $3.7M from $22.2M; G&A to $3.6M from $5.9M, reflecting cost reduction after LIFT-AD failure.","Phase 1 trial of ATH-1105 (ALS) showed favorable safety, dose-proportional PK, and CNS penetration; preparation for future ALS trial ongoing.","Company continues to explore strategic alternatives with Cantor Fitzgerald; fosgonimeton development paused."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156860,"accession_number":"0000950170-25-080234","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Athira shareholders approve reverse stock split at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class II director nominees elected: Joseph Edelman, John M. Fluke Jr., Grant Pickering.","Ratification of Ernst & Young as independent auditor approved (26,981,568 for).","Proposal to authorize reverse stock split approved (21,915,867 for, 4,835,818 against).","Board may set final split ratio from 5:1 to 20:1 in its discretion.","Quorum of 71.58% of shares present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156859,"accession_number":"0000950170-25-068020","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q1 net loss narrows to $9.1M; ATH-1105 Phase 1 complete, ALS dosing on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments totaled $36.7M as of March 31, 2025, down from $51.3M at year-end 2024.","Net loss for Q1 2025 was $9.1M ($0.23 per share) vs $26.3M ($0.69 per share) in Q1 2024.","R&D expenses fell to $4.3M from $21.2M, driven by fosgonimeton program cuts after failed LIFT-AD trial.","ATH-1105 Phase 1 healthy volunteer study completed; full data expected 2H25, ALS patient dosing to begin late 2025.","Company exploring strategic alternatives with Cantor Fitzgerald after discontinuing fosgonimeton development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156858,"accession_number":"0000950170-25-054707","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Athira Pharma transfers to Nasdaq Capital Market; must regain $1 bid price by Oct 13, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved transfer from Nasdaq Global Select Market to Capital Market effective April 17, 2025.","Failed to meet $1 minimum bid price; granted 180-day grace period until October 13, 2025.","Must have bid price ≥ $1 for ten consecutive business days during grace period to regain compliance.","Seeking stockholder approval for reverse stock split at its 2025 annual meeting.","Stock continues trading under symbol 'ATHA' on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175263,"accession_number":"0000950170-25-029038","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma FY2024 net loss $96.9M; cash burn continues; ATH-1105 Phase 1 complete; fosgonimeton paused","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments $51.3M as of Dec 31, 2024, down from $147.4M; net cash used in operations $97.2M.","Net loss $96.9M ($2.52 per share) vs $117.7M ($3.09 per share) in 2023; R&D expenses $70.7M, G&A $26.1M.","Legal expense $4.1M accrued for settlement with DOJ related to NIH grant.","ATH-1105 Phase 1 in 80 healthy volunteers completed with favorable safety; on track to dose ALS patients in 2025.","LIFT-AD Phase 2/3 of fosgonimeton missed endpoints; development paused; exploring strategic alternatives with Cantor Fitzgerald."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192211,"accession_number":"0000950170-24-123324","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q3 net loss $28.7M; LIFT-AD missed endpoints; exploring strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $28.7M ($0.75/sh) vs $33.0M ($0.87/sh) Q3 2023; cash $68.9M down from $147.4M at Dec 2023.","Fosgonimeton (ATH-1017) LIFT-AD Phase 2/3 missed primary and key secondary endpoints; development paused.","Exploring strategic alternatives with Cantor Fitzgerald; ATH-1105 Phase 1 healthy volunteers on track for year-end 2024.","R&D expenses $17.9M vs $27.2M; G&A $7.6M vs $7.8M; legal accrual $4.1M from DOJ investigation.","Plan to begin dosing ATH-1105 in ALS patients in 2025; preclinical data supports HGF-modulating mechanism."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192210,"accession_number":"0000950170-24-115592","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Athira Pharma receives Nasdaq bid price deficiency notice; stock below $1 for 30 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Oct 16, 2024 for non-compliance with minimum bid price of $1.00.","Has 180 calendar days (until April 14, 2025) to regain compliance by closing at $1.00+ for 10 consecutive days.","May seek stockholder approval for reverse stock split if needed to cure deficiency.","Also plans to file new $300M shelf registration S-3 to replace expiring 2021 registration.","If not compliant by deadline, may transfer to Nasdaq Capital Market for additional 180-day cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192209,"accession_number":"0000950170-24-113210","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Athira Pharma terminates CFO/CBO and COO/CDO; grants retention equity to CEO and VP Finance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Gengos (CFO/CBO) and Rachel Lenington (COO/CDO) terminated Oct 1, 2024; severance payments of $363,750 and $375,000 respectively.","Lenington to provide consulting through Dec 31, 2024 at $41,666.67/month; equity vests during term.","CEO Mark Litton receives 325k RSUs + 325k options (strike $0.4257); VP Finance Renninger gets 37,077 RSUs + 37,077 options (strike $0.4499).","Retention awards vest 1/3 each on Dec 31, 2024, Jun 30, 2025, and Dec 31, 2025, subject to continued service.","2024 corporate goal achievement percentage automatically increased by 25 percentage points for certain executives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208697,"accession_number":"0000950170-24-107031","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Athira cuts 70% of workforce, pivots to ATH-1105 after LIFT-AD readout","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~70% (49 positions); one-time costs ~$2.8M third-quarter 2024.","Annualized cost savings ~$13.4M; cash runway extended into Q1 2026.","CFO Andrew Gengos and COO Rachel Lenington terminated without cause, effective Oct 1, 2024.","VP Finance Robert Renninger appointed principal financial and accounting officer.","Focus shifts to ATH-1105 (oral HGF modulator) for ALS; Phase 1 completes by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208696,"accession_number":"0000950170-24-102788","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Athira's Phase 2/3 LIFT-AD trial of fosgonimeton misses primary endpoint; biomarker data mixed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint GST (p=0.70) and key secondary endpoints ADAS-Cog11 (p=0.35) and ADCS-ADL23 (p=0.61) not met; directionally favored fosgonimeton.","Prespecified subgroups (moderate AD, APOE4 carriers) showed numerically greater treatment effects; e.g., moderate AD ADAS-Cog11 delta -1.16 (p=0.39).","Biomarker p-Tau217 significantly reduced (p<0.01); NfL, GFAP, Aβ42/40 improved directionally.","Preliminary cash resources ~$75.1M as of Aug 31, 2024; ATH-1105 Phase 1 ongoing, completion expected by year-end 2024, ALS patients targeted for 2025.","Fosgonimeton well tolerated; SAEs similar to placebo; 22% early termination rate; full results to be presented at CTAD Oct 29-Nov 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208695,"accession_number":"0000950170-24-089281","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q2 net loss $26.9M; LIFT-AD topline data expected Sept 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments were $91.8M as of June 30, 2024, down from $147.4M at Dec 31, 2023.","Net loss of $26.9M ($0.70 per share) for Q2 2024 vs. $29.6M ($0.78 per share) in Q2 2023.","R&D expenses $22.2M (up from $21.6M) driven by ATH-1105 Phase 1 trial; G&A down to $5.9M from $10.0M.","Topline data from Phase 2/3 LIFT-AD trial of fosgonimeton in Alzheimer's targeted for September 2024; full data at CTAD in October.","Phase 1 trial of oral ATH-1105 for ALS underway; first cohort completed, expected completion by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226427,"accession_number":"0000950170-24-065914","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Athira Pharma shareholders approve officer liability limitation charter amendment at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors Kosacz, Litton, and Panzara elected with For votes ranging from 77% to 82% of votes cast (excl. broker non-votes).","Ratification of Ernst & Young as auditor passed: 27,199,785 For, 59,069 Against, 99,855 Abstain.","Amendment to certificate of incorporation limiting officer liability approved: 19,365,835 For, 602,307 Against, 347,812 Abstain.","Broker non-votes were 7,042,755 on director election and charter amendment proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226426,"accession_number":"0000950170-24-061837","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Athira Pharma obtains preliminary approval for derivative lawsuit settlement with governance reforms","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court preliminary approval on May 3, 2024; final hearing set for July 18, 2024.","Settlement requires Athira to adopt corporate governance reforms and pay lead plaintiffs' attorney's fees, expenses, and service awards.","Derivative actions Bushansky v. Kawas and Houlihan v. Kawas covered by the Stipulation of Settlement dated March 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226425,"accession_number":"0000950170-24-060452","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q1 2024 net loss $26.3M ($0.69/share); cash $122.1M; LIFT-AD data H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $26.3M ($0.69/share) vs $27.8M ($0.73/share) in Q1 2023; operating cash burn $25.8M.","Cash and investments $122.1M as of March 31, 2024, down from $147.4M at year-end 2023.","LIFT-AD Phase 2/3 topline data for fosgonimeton in Alzheimer's expected H2 2024; enrollment complete.","IND submitted for ATH-1105 (ALS); first-in-human study expected to start Q2 2024.","Appointed Javier San Martin, M.D. as Chief Medical Officer in April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}